-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
N-Hydroxyurea
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/127-07-1.gif)
| Category | Human immunodeficiency Virus (HIV) |
| CAS | 127-07-1 |
| Description | Hydroxyurea is an antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase. |
Product Information
| Synonyms | NSC-32065; Hydroxycarbamide; Hydrea; 1-Hydroxyurea; Oxyurea; Biosupressin; Carbamohydroxamic acid; Litalir; N-Carbamoylhydroxylamine; Droxia; Siklos; Carbamoyl Oxime; Cytodrox; Hidrix |
| IUPAC Name | hydroxyurea |
| Molecular Weight | 76.05 |
| Molecular Formula | CH4N2O2 |
| Canonical SMILES | C(=O)(N)NO |
| InChI | InChI=1S/CH4N2O2/c2-1(4)3-5/h5H,(H3,2,3,4) |
| InChIKey | VSNHCAURESNICA-UHFFFAOYSA-N |
| Boiling Point | 136.04°C (Predicted) |
| Melting Point | 133-136°C (dec.) |
| Flash Point | 88.1±22.6 °C |
| Purity | >98% |
| Density | 1.457±0.06 g/cm3 (Predicted) |
| Solubility | Slightly soluble in DMSO, Water |
| Appearance | White to Off-white Solid |
| Application | Antineoplastic agents; antisickling agents; enzyme inhibitors; nucleic acid synthesis inhibitors |
| Storage | Store at 2-8°C under inert atmosphere |
| Animal Admin | To determine whether hydroxyurea would improve anemia and/or prevent or diminish the development of organ damage in the absence of HbF induction, hydroxyurea, at doses of 25 mg/kg, 50 mg/kg, and 100 mg/kg, or vehicle is administered five days per week to SCD mice. |
| Complexity | 42.9 |
| Exact Mass | 76.027277375 |
| Index Of Refraction | 1.501 |
| In Vitro | Hydroxyurea is used in a number of myeloproliferative, neoplastic, HIV, and non-hematological diseases. Treatment of cells in primary culture with 30 μM hydroxyurea for 96 hours significantly increases the fractional HbF content. The Gγ: Aγ- globin mRNA is induced 0.30- to 8-fold in vitro. Hydroxyurea has been shown to block HIV-1 reverse transcription and/or replication in quiescent peripheral blood mononuclear cells and macrophages. |
| In Vivo | Hydroxyurea therapy producs consistent reductions in WBC and ANC without improvement in anemia over 17 weeks Hydroxyurea at 50mg/kg produces a reduced white blood cell count, absolute neutrophil count and no improvement in anemia compared to vehicle treated sickle cell mice. |
| PSA | 75.35000 |
| Target | DNA/RNA Synthesis; Autophagy; Apoptosis; HIV |
| Vapor Pressure | 0.0±1.0 mmHg at 25°C |
| XLogP3-AA | -1.8 |
